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Abstract: Inflammatory bowel disease (IBD) is a chronic disease mediated by the immune system and
characterized by the inflammation of the gastrointestinal tract. This study is to understand how the
use of parenteral nutrition (PN) can affect the adult population diagnosed with IBD. We conducted
a systematic review, meta-analysis, and meta-regression. From the different databases (MEDLINE,
Scopus, Cochrane, LILACS, CINAHL, WOS), we found 119 registers with an accuracy of 16%
(19 registers). After a full-text review, only 15 research studies were selected for qualitative synthesis
and 10 for meta-analysis and meta-regression. The variables used were Crohn’s Disease Activity
Index (CDAI), albumin, body weight (BW), and postoperative complications (COM). PN has shown
to have efficacy for the treatment of IBD and is compatible with other medicines. The CDAI and
albumin improve, although the effect of PN is greater after a while. However, the effect on the
albumin could be less than the observed value in the meta-analysis due to possible publication bias.
The BW does not change after intervention. COM utilizing PN has been observed, although the
proportion is low. More studies specifically referring to ulcerative colitis (UC) and Crohn’s disease
(CD) are needed to develop more concrete clinical results.
Keywords: inflammatory bowel diseases; parenteral nutrition; systematic review; meta-analysis;
Crohn disease
1. Introduction
During the last decades, the prevalence of inflammatory bowel disease (IBD) has increased in the
U.S. and Europe [1]. Moreover, it has also increased in developing countries [2,3]; thus, IBD can be
considered a common disease in wide areas of the world.
IBD is a chronic inflammatory disease mediated by the immune system. IBD includes Crohn’s
disease (CD) and ulcerative colitis (UC). The altered response of the immune system leads to the
inflammation of the gastrointestinal tract clinically defined by relapsing and remitting episodes [4,5].
The inflammatory process is characterized by a long-term overproduction of pro-inflammatory factors
and an enhanced intestinal permeability [6]. IBD involves an inflammatory process of the intestinal
layers and could cause abdominal swelling, fever, fatigue, weight loss, abdominal pain, diarrhea,
bloody feces, etc. [7].
The European Society for Clinical Nutrition and Metabolism (ESPEN) has presented the guidelines
and recommendations on clinical nutrition for the IBD [8]. The etiology of the IBD is not still
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completely understood [9,10]. Many studies have indicated that the genetic predisposition, diet, the
environment, the intestinal microbial flora, and the immune responses are involved in the pathogenesis
of IBD [4,5,11,12].
Diet and intestinal microbial flora could change the inflammatory response of the gastrointestinal
tract [13,14]. Diet may reduce the symptoms and prevent the degenerative process of the IBD [15].
Therefore, it is considered a therapy for IBD [13]. Among the dietetic therapies for IBD, intestinal rest
by parenteral nutrition (PN) is considered a strategy to reduce the inflammatory response of intestinal
layers [16] and to recover from nutritional impairment [17]. The American Society for Parenteral and
Enteral Nutrition (ASPEN) and ESPEN have described the use of PN [18–20]. PN could be considered
a third way for human nutrition after oral intake and enteral nutrition. However, a combination of
them has been studied [21]. PN could not advantage in IBD compared to other nutrition therapies.
However, when the IBD patients are temporarily unable to receive significant oral or enteral nutrients,
PN could be used as a nutritional treatment [21,22]. Also, in severe cases of IBD with surgical resection
or bowel severe complications, PN could provide a supply of nutrients to maintain good nutritional
status and reduce inflammatory reactions [23].
The aim of this review was to understand the use of PN and its effects on adults diagnosed
with IBD.
2. Materials and Methods
To achieve this objective, a systematic review was conducted in agreement with the procedures and
verification list described by PRISMA [24]. Afterward, a meta-analysis on the more common results,
and a meta-regression with the co-variables, surgery (Yes/no), observed moment (days), and period of
treatment (days), were conducted.
2.1. Systematic Review
A search of scientific works was conducted in the MEDLINE database, through the system of
open retrieval system on the Internet such as PubMed, Cochrane, Scopus, Web of Science, CINAHL,
and LILACS. The studies conducted over time, up to 8 July 2019, were compiled.
2.1.1. Inclusion and Exclusion Criteria
The studies selected had to comply with the following inclusion criteria: refer to an adult
population (older than 18) diagnosed with IBD; study the effect of PN within IBD; be clinical trials;
in English, Spanish, Portuguese, French, or German languages.
The following articles were excluded: those that referred to the infant population; to animals,
to the use of PN in a healthy adult population; those that sought the effect of oral exclusion diets on
IBD; that were observational studies; that were based on secondary sources.
2.1.2. Search Equation
To include content linked to the intervention, PN, a specific descriptor was used (MeSH), such as
“Parenteral Nutrition, Total”, and the term “Parenteral Nutrition” in the title or abstract.
For the content linked to the population, we utilized the descriptor that referred to the disease
“Inflammatory bowel diseases”, and its equivalent term in the title or abstract.
Also, the filters “Humans”, “Adult”, and “Clinical Trial” were utilized to achieve our objective.
Therefore, the main search equation designed for this study was:
((“Inflammatory Bowel Diseases” [Mesh] OR “Inflammatory Bowel Diseases” [Title/Abstract])
AND (“Parenteral Nutrition, Total” [Mesh] OR “Parenteral Nutrition” [Title/Abstract])) AND (Clinical
Trial [ptyp] AND Humans [Mesh] AND adult [MeSH])
The search equation was adapted to each, and all of the databases described previously. The process
was conducted between the months of June and July 2019.
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2.1.3. Selection Process
After eliminating duplicate records, the process of selection was conducted in two phases. The first
consisted of reviewing the titles and abstracts of all the article records resulting from the adapted search
equations and shown by the databases by using the inclusion and exclusion criteria and the objective of
the study as the screening measure. The screening and selection of the records/articles were conducted
independently by the two researchers, both experts in the fields of nutrition. These researchers agreed
on the discrepancies found in order to define the final suitability of the records/articles found in
the databases. The precision of the search was calculated based on the ratio of the full-text articles
selected for the review divided by the number of records found by the search equation, multiplied by
one hundred.
The second phase was conducted by applying the inclusion/exclusion criteria to the complete text
of all the scientific studies selected in the first phase, thus ensuring the relevance of each one of them.
2.1.4. Evaluation of the Quality of the Studies
The evaluation of the methodological quality of the included studies was performed by two
independent researchers, using the CONSORT (Consolidated Standards of Reporting Trials) guide
for clinical trials. This guide contains a list of 25 essential aspects that should be described in the
publication of these studies. For each selected study, one point was assigned for each item present
(if not applicable, it did not score). When an item was composed of several points, these were evaluated
independently, giving the same value to each of them and subsequently an average was made (being the
final result of that item), so that in no case could it beat the score of one point per item [25,26].
2.2. Meta-Analysis and Meta-Regression
To calculate the effect size of the enteral nutrition on the variables, Crohn’s Disease Activity
Index (CDAI), albumin, postoperative complications (COM), and body weight (BW), a meta-analysis
was performed. For this, the model of fixed effects and the model of random effects were utilized.
The results were presented as a forest-plot, along with the percent Heterogeneity and its confidence
interval at 95%, the T-value, and the heterogeneity test.
To explore the influence of each study over the effect size, we used a leave-one-out method; pooled
estimates were calculated omitting one study at a time. In addition, we plotted a scatter plot introduced
by Baujat et al. [27]. On the x-axis, the contribution of each study to the overall heterogeneity statistic
is plotted. On the y-axis, the standardized difference of the overall treatment effect with and without
each study is plotted; this quantity describes the influence of each study on the overall treatment effect.
Therefore, studies that fall in the top right quadrant of the Baujat plot have the most influence.
Publication bias occurs when only favorable results are published, and this could have
consequences on the results of the meta-analyses if these were included. To analyze the publication
bias, a non-parametric analysis was conducted as proposed by Duval and Tweedie [28] based on
the funnel-plot, estimating, and adjusting for the number and outcomes of missing studies in the
meta-analysis. Another less-conservative proposal to estimate the number and outcomes of missing
studies is the proposal by Copas et al. [29].
The meta-regression was utilized to understand if the duration of the intervention (days) or the
surgery (yes/no) or observed moment (days) modified the effect size of the resulting variables CDAI,
albumin, and BW. The effect size of COM was only related to the duration of the intervention. All the
calculations were conducted within an R programming environment utilizing the packages meta
version 4.9-6 [30] and metasens version 0.4-0 [31].
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3. Results
3.1. Systematic Review
As a result of the specific search equations used on the different databases, a total of 145 records
were found of scientific articles. A total of 26 records were duplicated, leaving a total of 119 records
without duplication. In the first phase of the study, exactly 100 study records were discarded, leaving
19 full-text studies to review, so that the accuracy was 16%. The reasons for not including them were
that 51 records showed that the study utilized a design that was not adequate, 15 did not use an adult
population, 16 did not study the effect of PN, three were written in another language other than the
ones cited above, (one in Japanese, one in Chinese, and one in German), 11 did not refer to the IBD,
and four were still being conducted without showing results (Figure 1).
In the second phase, four trials were removed, three due to defects in its design, and one, because
the patients studied, were not diagnosed with IBD. Therefore, only 15 research studies [32–46] were
selected, as shown in Figure 1.
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As for the designs of the studies included, 11were controlled and randomized clinical
studies (73.4%), two non-randomized, controlled clinical trials (13.3%), and two non-randomized,
non-controlled clinical trials (13.3%) were found. In addition, six of the studies found showed results
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that specifically referred to CD, one study to UC, and 11 studies had results on UC and CD, under
the category of IBD. Also, 10 studies mentioned the results of the disease in its active form and five
studies report disease outcomes in patients under surgery. Figure 2 shows this information in a
chronological manner.
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As for the variety of the components of formulas employed, each study used its own
formulas, normally supplemented with vitamins, minerals, and electrolytes. However, some studies
employed the following commercial components/complements: “Freamine®”, “Amigen®”, “Uniasa®”,
“Dipeptamin®”, “Aminoplasmal®”, “Vamin®”, “Addamel®”, “Soluvit®”, and “Vitalipid®”.
In addition, a total of four types of objectives were found: six studies sought to compare the
administration of PN with other techniques such as dextrose and electrolyte solutions, intravenous
transfusions or oral diet, as long as possible; five studies compared PN with EN, among which, three
with elemental formulas, and two with polymeric formulas; two studies sought to experiment with PN
and two studies compared the same PN, but with some different component/form of withdrawal.
As for the manner of administration of the PN, the research studies generally employed a central
venous catheter with the aid of an infusion pump.
The total population analyzed in the research studies found included a total of 557 individuals
with IBD, with 382 diagnosed with CD, and 152 with UC.
The main tools utilized by the researchers to obtain the results were the scores, biomarkers,
and tests to measure the activity of the disease—the CDAI, the Van Hees activity index (VHAI),
the Truelove and Witts index; biomarkers such as CRP, ESR, the white blood cell count (WBC), levels of
albumin, pre-albumin, transferrin, hemoglobin, platelet count, total bilirubin, alkaline phosphatase, etc.;
and medical tests, such as the ileocolonoscopy. Complementary tests, such as urine and feces samples.
Tests to measure the body’s composition, such as anthropometries and bioimpedance, to obtain
parameters such as body weight (BW), triceps skinfold thickness (TSF), mid-arm muscle circumference
(MAMC), etc. The follow-up of complications by health professionals, whether postoperative or
during experimentation, such as infections, septicemias, cases of pneumonia, intestinal obstructions,
pancreatitis, fever, hypoglycemia, hyperglycemia, etc.
Table 1 shows the main results schematically, found in the selected articles and Table 2 shows the
scores obtained by the studies for their methodological quality according to the CONSORT guide.
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Table 1. Main results of the systematic review.
Author Study n/Age Disease P/d CC Treatment Variables Main Results
Goode et al.,
1976 [32] UNRCT
8/NI
M NI
F NI
SUR
CD 360 GB
Intravenous feeding through
an elemental diet in the
whole sample
BW, nitrogen balance, TBF
measured by anthropometry,
TBK.
3 (37.5%) preoperative patients were able to restore 10% of
their lost lean tissue per month with an ED, which contained
12 g/day of nitrogen. In the five (62.5%) postoperative
patients who had a successful resection, the rate of
restoration of the lean tissue mass was 18.5% per month with
a nitrogen intake in the elemental form of 10 g/day. In all the
patients given an ED, it was possible to restore all the lean
tissue loss.
Dickinson
et al., 1980 [33] RCCT
40/41,75
M 13
F 27
ACT
IBD
EG/CG
20/20
18 GB
EG: 2–3 L/day of “Freamine®”
intravenous solution (dextrose,
electrolytes, and vitamins) via
the central venous catheter
CG: blood, albumin, and,
normal diet plus vitamins
(Multibionta, Merck).
All groups: Prednisone
40 mg/day
BW, TBN, patients to
colectomy, patients who reduce
prednisone to 10 mg/day
The mean time to reduce prednisone to 10 mg/day was
23.7 ± 6.0 days for the control patients and 21.2 ± 3.7 days
for the EG, respectively. Six (30%) patients in the CG and
nine (45%) patients in the EG came to surgery. In CG,
11 (55%) patients responded medically and in EG 10 (50%)
patients. The CG lost significantly 108 g of TBN (7.3% of
body protein mass) while in the EG, there was no change.
However, the weight gain observed in both groups did not
reflect changes in TBP.
Elson et al.,
1980 [34] UNRCT
30/23
M 14
F 16
ACT
IBD
CD: 20
UC: 10
CD:36
UC:21 US
TPN: Synthetic formulation
(Freamine®) and a protein
hydrolysate (Amigen®).
Ampule multivitamins,
folic acid, and water.
Weight gain, Nitrogen balance,
albumin and symptoms such
as abdominal pain, diarrhea,
fever, rectal bleeding, fistula,
obstruction, abdominal mass,
proctoscopy
change, hematocrit, and blood
transfusion requirement.
CD: All patients gained weight. Weight changed from 6.6 kg
of loss to 6.8 kg of gain. There was a small increase in
albumin from 2.7 to 3.2. 13/20 (65%) patients had a positive
clinical response. TPN improved symptoms such as diarrhea
and pain and a sense of well-being, but not the rest.
Nonresponse was found in 3/4 (75%) patients receiving TPN
primarily to heal fistulas. Although complications were
frequent and 10 (50%) patients were eventually operated.
UC: 9/10 (90%) patients gained weight. Weight changed from
9.3 kg of loss to 3.6 kg of gain after TPN. 4/10 (40%) patients
had a positive response to TPN. Complications were
common, and 6/7 patients were having a colectomy.
McIntyre et al.,
1986 [35] RCCT
47/36
M 19
F 28
ACT
IBD
EG/CG
27/20
7 GBFR
EG: PN and water.
CG: oral diet.
All groups: 60 mg/day
prednisolone.
The operation and mortality
rates, clinical, and laboratory
data, such as stool weight,
albumin, HB, ESR, WBC, etc.
There was no significant difference between the groups for
any parameter measured. Within each group the stool
weight and stool frequency decreased significantly in EG
(p < 0.01), between days 0 and 7 but not in CG. The ESR was
significantly reduced in both groups (p < 0.01). In CG, serum
albumin concentrations increased significantly compared
with day 0 (p < 0.02). 11 (40.7%) patients in EG and 5 (25%)
patients in CG required surgery. There were two deaths
during the hospital admission, one in each group. Surgical
treatment was required by 14 of 27 patients with UC but
none of 16 with CD (p < 0.01).
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Table 1. Cont.
Author Study n/Age Disease P/d CC Treatment Variables Main Results
Fasth et al.,
1987 (a) [36] RCCT
92/51
M NI
F NI
SUR
Cancer/
IBD(REM)/
IBD (ACT)
50/16/26
EG/CG
48/44
9.7 SE
EG: TPN composed of amino
acid solution, 20% fat, and 10%
dextrose.
CG: a 10% dextrose and
electrolytes solution
Postoperative complications
The total mortality was 2 (2.2%) in 92 operations. Forty-eight
early complications after major colorectal surgery were
diagnosed in 33 (36%) patients in the whole sample. There
was no morbidity associated with the central venous lines or
the TPN treatment per se. The overall complication rate in
both groups was similar, without significant differences.
Fasth et al.,
1987 (b) [37] RCCT
92/51
M NI
F NI
SUR
Cancer/
IBD(REM)/
IBD (ACT)
50/16/26
EG/CG
48/44
9.7 SE
EG: TPN composed of amino
acid, 20% fat, and 10% dextrose.
CG: a 10% dextrose and
electrolytes solution
Albumin, BW, TBK, TSF, TBW,
nitrogen balance
The cumulative nitrogen balance after one week was +0.1 g
in TPN-patients, and −47.3 g in controls (p < 0.001).
The difference in relative weight loss between TPN and
control patients was statistically significant at 1, 2, 4, 8, and
24 weeks (group cancer), at 1, 2, and l 4 weeks (group
IBD-REM) and at 2 weeks (group IBD-ACT). The reduction
in TBK was significantly less in the TPN-patients of group
cancer and IBD-REM than in the controls. In all three groups,
TPN-patients had a higher mean value than controls at every
postoperative measurement for TSF. This difference between
TPN and controls reached statistical significance only in
group IBD-REM at 1 and 4 weeks, and in group IBD-ACT at
2 weeks. After the first week, the albumin in groups cancer
and IBD-REM increased towards the preoperative levels.
The increase was faster in TPN patients, and a statistically
significant difference was found in group IBD-REM at 8 and
24 weeks.
Jones 1987 [38] RCCT
36/31
M 9
F 27
ACT
CD
EG/CG
19/17
14 GB
EG: TPN with
0.17–0.3 g N × kg−1,
electrolytes, all vitamins,
and water.
CG: 300–500 g of ED “EO28”
CDAI, albumin,
orosomucoid, ESR.
No difference was detected in the success rate, the speed of
achieving remission, the changes in CDAI, erythrocyte
sedimentation rate (ESR) and serum albumin between the
two groups. The fall in the CDAI in both groups was
significant (p < 0.01).
Greenberg GR
et al., 1988 [39] RCCT
51/30
M 25
F 26
ACT
CD
TPNG/
ENG/PPNG
17/19/15
21 CA
TPNG: TPN more water, plus
an ampule of vitamins per day.
ENG: formula diet
“Precision-Isotonic”.
PPNG: Unrestricted diet and a
partial protein/calorie PN.
CDAI, nutritional assessment
and biochemical measurements
(hematocrit, blood glucose,
electrolytes, creatinine,
magnesium, and albumin).
The average CDAI decreased (p < 0.01) with no significant
differences between groups. Remission rates to discharge
were similar among the three groups: 12 (70.6%) patients in
TPNG, 11 (57.9%) patients in ENG, and 9 (60%) patients in
PPNG (X2 1.42 and 1.15; p = n/s). Remission rates of 42% in
TPNG, 55% in EN and 56% in PPNG at 12 months were
equivalent and not influenced by the type of nutritional
support initially administered. In the whole sample,
at 12 months, 18 (35%) patients required surgery, 17 (34%)
were medically treated for relapse, and 16 (31%) had
sustained remission.
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Table 1. Cont.
Author Study n/Age Disease P/d CC Treatment Variables Main Results
Abad-Lacruz A
et al., 1990 [40] RCCT
29/32
M 15
F 14
ACT
IBD
PG/TPNG
16/13
17.4 ES
PG: Polymeric diet high in
nitrogen “UNIASA” by
nasogastric tube.
TPNG: Specific total PN by a
central vein.
Biochemical measurements
(serum albumin, GGT, ALT,
AST, etc.) and VHAI and the
Truelove and Witts index were
measured.
PG had a significant increase in albumin concentration
(32 ± 1 to 38.2 ± 1.6 g/liter; p < 0.01). There was lower disease
activity in both groups (3.31 ± 0.15 to 2.31 ± 0.24, p < 0.05 in
PG; and 3.38 ± 0.21 to 2.61 ± 0.27, p < 0.05 in TPNG). 8 (5 CD
and 3 UC) of 13 patients (61.5%) in the TPNG group
developed abnormalities in LFT, while in the PG group,
it only occurred in 1/16 (6.2%) patients (p = 0.002).
Wright RA
et al., 1990 [41] RCCT
11/NI
M 7
F 4
ACT
CD
TENG/
TPNG
6/5
14 US
TENG: Total elemental enteral
feeding “Vital”
TPNG: Total peripheral PN.
CDAI, standard
anthropometric parameters,
nitrogen balance studies and
chemical profiles.
CDAI improved significantly in both groups. Plasma
transferrin levels and TLC improved in the TENG group
(p < 0.05). No significant differences in weight gain. TLC
improved in all patients receiving EN but did not change
significantly in those receiving PN. Improvement in serum
transferrin levels correlated positively (p < 0.05) in patients
receiving EN but not in PN.
González-Huix
et al., 1993 [42] RCCT
42/33,25
M 21
F 21
ACT
UC
TENG/TPNG
22/20
16 ES
TENG: Polymeric EN,
administered intragastrically.
TPNG: All in one admixture
PN with a composition similar
to that of TEN.
TSF, MAMC, BW, %IBW,
albumin, complications
attributable to ANS, score
Truelove, and Witts.
No significant changes were observed in anthropometric
parameters at the end of either TENG or TPNG treatment.
However, a significant increase in albumin concentration
was observed in the TENG (p = 0.015). As a consequence,
the median increase in albumin values was significantly
higher in patients on TENG 16.7% (−0.5 to +30.4%) than on
TPNG 4.6% (−12.0 to+ 13.7%) (p = 0.019). Ten patients in
each group required colectomy. Postoperative infections
occurred significantly more often in patients on TPNG than
in those on TEN (p = 0.028). There were significantly more
ANS-related complications in the TPNG than in the TENG
(35% vs. 9%; p = 0.046).
Eisenberg
et al., 1995 [43] RCCT
12/37,7
M 6
F 6
ACT
IBD/SBF/II
10/1/1
1.5 US
AS: Abrupt interruption TPN
with steroids.
AWS: Abrupt interruption TPN
without steroids.
TS: Taper interruption TPN
with steroids.
TWS: Taper interruption TPN
without steroids.
Glycemic symptom by
questionnaire, pulse, blood
samples for glucose, insulin,
growth hormone, cortisol,
epinephrine, norepinephrine,
and glucagon.
Plasma concentrations of glucose decreased significantly
(p < 0.001) after tapered and abrupt discontinuation of TPN
infusion in all 12 patients without differences between these
methods, and no patient experienced clinical symptoms of
hypoglycemia. Mean norepinephrine and epinephrine levels
were only slightly higher after abrupt discontinuation,
compared with tapering of TPN, without significant
differences. Physiologic responses were also not statistically
different after the two methods of discontinuation. Mean
levels of insulin decreased significantly after discontinuation
of TPN (p < 0.001), but peripheral glucagon levels remained
essentially unchanged in all groups. No statistical difference
between methods for cortisol and growth hormone.
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Table 1. Cont.
Author Study n/Age Disease P/d CC Treatment Variables Main Results
Ockenga et al.,
2005 [44] RCCT
24/35
M 15
F 9
ACT
IBD
TPN+/TPN-
12/12
21.5 DE
TPN+: TPN with
alanyl-glutamine
“Dipeptamin®”.
TPN-: TPN with a standard
aminoacid solution
“Aminoplasmal®”.
All patients: mesalazine and
prednisolone 0.5–1 mg/kg/day
or azathioprine.
LOS, CDAI, BMI, blood sample
for HB, hematocrit, WBC,
albumin, CRP, urea, and AA.
Intestinal permeability,
Glutamine plasma levels did not change significantly in
either group throughout the study. BMI, albumin level,
citrulline, or arginine levels did not change significantly in
either group. Glutamine supplementation did not appear to
produce any significant difference in D-lactulose/xylose ratio
(TPN+: 0.01 vs. TPN-: 0.02; p = 0.82) and it exerted no
specific effect on CDAI, WBC, or total lymphocyte count
compared to standard TPN. The duration of TPN and LOS
did not differ significantly between groups.
Yao et al., 2005
[45] NRCCT
32/29
M 19
F 13
SUR
CD
EG/CG
16/16
21 CN
EG: Perioperative PN
CG: intravenous transfusions
containing energy 20
kcal/kg/day, normal water,
and diet
Serum IgM, IgG, and IgA, LF,
bilirubin levels, BMI, BW, BH,
postoperative complications.
IgM levels decreased significantly three weeks after surgery
only in EG. BMI increased significantly in EG, and no change
in CG. There were no significant changes in concentrations of
IgG and IgA. The overall complication rates of both groups
were similar.
Jacobson 2012
[46] NRCCT
120/35
MEG 4
FEG 11
SUR
CD
EG/CG
15/105
46 SE
EG: TPN preoperative
(amino acids “Vamin®”,
carbohydrates, fat emulsion
“Intralipid ®”, electrolytes,
trace elements “Addamel®”,
and vitamins “Soluvit®
and Vitalipid®”).
CG: Patients operated without
preoperative TPN.
Early postoperative
complications and biochemical
blood parameters.
During the preoperative TPN, all the cases in EG displayed
clinical remission of CD. There was no significant
postoperative complication in the EG, whereas there were 29
(27.6%) patients with postoperative complications in CG.
This is a higher rate of complications (p < 0.05) than in EG.
There was a significant increase in the variables with TPN
preoperative: BW, BMI, albumin, haptoglobin, cholesterol,
triiodothyronine, Ig A, Ig M, phospholipids total, lecithin.
There was also a significant decrease in the variables: White
cell count, haptoglobin, and triglycerides.
%IBW: Percentage of ideal body weight. AA: Plasma amino acid concentration. ACT: Active disease. ALT: Alanine aminotransferase. ANS: Artificial nutritional support. AST: Aspartate
aminotransferase. BMI: Body mass index. BW: Bodyweight. CC: ISO Country Codes. CD: Crohn Disease. CDAI: Crohn’s Disease Activity Index. CRP: C-reactive protein. ED: Elemental
diet. EG/CG: Experimental and Control Group. EN: Enteral Nutrition. ESR: erythrocyte sedimentation rate. F: Female. GGT: γ-glutamyltransferase. HB: Hemoglobin. HEEH: Home
elemental enteral hyperalimentation. IBD: Inflammatory Bowel Disease. IBD: Inflammatory Bowel Disease. IBW: Ideal body weight. II: Intestinal inertia. LFT: Liver function test.
LOS: Length of hospital stay. M: Male. MAMC: Mid-arm muscle circumference. N: Nitrogen. NI: Not indicated. NRCCT: Non-randomized controlled clinical trials. P/d: Period (days).
PN: Parenteral nutrition. RCCT: Randomized controlled clinical trials. REM: Disease in remission. SBF: Small bowel fistula. SUR: Surgery. TBF: Total body fat. TBK: Total body potassium.
TBN: Total body nitrogen. TBP: Total body protein. TBW: Total body water. TEN: Total enteral nutrition. TLC: Total lymphocyte count. TPN: Total parenteral nutrition. TSF: Triceps
skinfold thickness. UC: ulcerative colitis. UNRCT: Uncontrolled and non-randomized clinical trial. VHAI: Van Hees Activity Index. WBC: White blood cells.
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Table 2. Methodological quality analysis according to the CONSORT guide [25] for reporting clinical trials.
Studies 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 TotalScore (%)
Goode et al., 1976
[32] 0 1 0 0.5 0 0.5 0 NA NA NA NA 0.5 NA 0 0 0 0 NA 0 1 1 1 NA NA NA 5.5/16 34.4
Dickinson et al.,
1980 [33] 0 1 0.5 1 1 0.5 0 0 0 0 0 0 1 1 1 1 0 0 1 1 1 1 0 0 0 12/25 48
Elson et al., 1980
[34] 0 1 0.5 1 1 0.5 0 NA NA NA NA 0 NA 0.5 1 1 0 NA 1 1 1 1 NA NA NA 10.5/16 65.6
McIntyre et al.,
1986 [35] 0 1 0 0.5 1 1 0 1 0 0 0 0.5 1 1 1 1 0 1 1 1 1 1 0 0 0 14/25 56
Fasth (a) et al.,
1987 [36] 0 1 0.5 0.5 1 1 0.5 0 0 0 0 0.5 1 1 0 1 0.25 1 1 1 1 1 0 0 1 14.25/25 57
Fasth (b) et al.,
1987 [37] 0 1 0.5 0.5 1 0.5 0 1 0 0 0 0.5 1 1 1 1 0.25 0 1 1 1 1 0 0 1 14.25/25 57
Jones 1987 [38] 0.5 1 0.5 1 1 0.25 0 0 0 0 0 0 1 1 1 1 0.25 0 1 0 1 1 0 0 1 12.5/25 50
G.R. Greenberg
et al., 1988 [39] 0 1 0.5 1 1 1 0 1 1 0 1 1 0.5 1 1 1 0.25 0 1 1 1 1 0 0 0 16.25/25 65
A. Abad-Lacruz
et al., 1990 [40] 0.5 1 0.5 0.5 1 0.5 0 1 0 0 0 1 1 0.25 1 1 0.5 0 1 0 1 1 0 0 0 12.75/25 51
R. A. Wright et al.,
1990 [41] 0 1 0.5 0.5 1 0.5 0 0.5 0 0 0 1 0.5 0.75 0 1 0.25 0 0 1 1 1 0 0 1 11.5/25 46
González-Huix
et al., 1993 [42] 0 1 0.25 0.5 1 0.5 0 0 0 0 0 1 1 1 1 1 0.25 0 1 0 1 1 0 0 0 11.5/25 46
Eisenberg et al.,
1995 [43] 0 1 0.5 1 1 0.5 0 0 0 0 0 1 1 0 0 1 0.5 0 1 0 1 1 0 0 1 11.5/25 46
Ockenga et al.,
2005 [44] 0.5 1 0.5 1 1 0.5 1 1 1 0 1 1 1 0.5 1 1 0.25 0 1 1 1 1 0 0 1 18.25/25 73
Yao et al., 2005
[45] 0.5 1 0 0.5 1 0.5 0 NA NA NA NA 1 1 0 1 1 0.25 NA 1 0 1 1 NA NA NA 10.75/17 63.2
Jacobson 2012
[46] 0.5 1 0 0.5 1 0.5 0 NA NA NA NA 1 1 0.5 1 1 0.25 NA 1 1 1 1 NA NA NA 12.25/17 72.1
NA: Not applicable.
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3.2. Meta-Analysis and Meta-Regression
Only 10 clinical trials had common quality and variables needed to be used in the meta-analysis.
These 10 trials worked with a total of 26 groups. The final size of the sample was comprised by
298 observed moments for 164 individuals, all with IBD, to which a PN treatment had been given.
The common variables were the CDAI, albumin, BW, and COM, and the co-variables; duration of the
intervention, surgery, and observed moment. Figure 3 shows the effect size of the use of PN. For the
CDAI and albumin, the effects are positive when comparing the situation at the start and finish of
the treatment with PN, independently of whether the situation with fixed effects (less probable) or
random effects (more acceptable) was considered. However, for BW, the use of PN was not significant.
For COM, the effect size was significantly different from zero but the 95% confidence interval was close
to zero ([0.02; 0.63]).
The influence of each study on the results of the meta-analysis are shown in Table 3, considering a
model of random effects. For CDAI, the study of Greenberg et al. has a strong effect on the results,
increasing the effect size of the PN on the CDAI. The outcomes of Fasth et al. study has the strongest
influence on the albumin, but it is only 5%. All studies are homogeneous for the BW. Elson et al.
worked with two groups, one showed 0/10 of COM but the other showed 6/6; therefore, their study has
a strong influence on the results.
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Table 3. I fluence analysis in a meta-analysis using the leave-one-out method (R ndom effect).
Meta-Analysis for:
Effect Size (%He erogeneity)
ID O itting CDAI Albumin BW COM
1 1980 Elson et al. [34] 10 39.6% (95.5%)
2 1980 Elson et al. [34] 6 16.0% (75.0%)
3 1987 Fasth (a) et al. [36] 12 34.2% (95.9%)
4 1987 Fasth (a) et al. [36] 11 32.0% (95.9%)
5 1987 Fasth (b) et al. [37] 12 3.0 (86.1%) 0.49 (0.0%)
6 1987 Fasth (b) et al. [37] 12 3.0 (86.2%) 0.49 (0.0%)
7 1987 Fasth (b) et al. [37] 12 3.1 (86.3%) 0.62 (0.0%)
8 1987 Fasth (b) et al. [37] 12 3.3 (85.8 ) 0.59 (0.0%)
9 1987 Fasth (b) et al. [37] 12 3.5 (82.8%) 0.59 (0.0%)
10 1987 Fasth (b) et al. [37] 12 3.6 (80.1%) 0.49 (0.0%)
11 1987 Fasth (b) et al. [37] 11 2.6 (85.1%) 0.28 (0.0%)
12 1987 Fasth (b) et al. [37] 11 2.5 (84.3%) 0.34 (0.0%)
13 1987 Fasth (b) et al. [37] 11 2.6 (84.5%) 0.42 (0.0%)
14 1987 Fasth (b) et al. [37] 11 2.7 (85.1%) 0.52 (0.0%)
15 1987 Fasth (b) et al. [37] 11 2.8 (85.9%) 0.55 (0.0%)
16 1987 Fasth (b) et al. [37] 11 3.1 (86.3%) 0.53 (0.0%)
17 1987 Jones et al. [38] 16 −85.8 (77.8%) 3.2 (86.3%)
18 1988 Greenberg et al. [39] 19 −78.6 (59.4%) 3.1 (86.3%) 0.04 (0.0%)
19 1990 Abad-lacruz et al. [40] 13 3.2 (86.3%)
20 1990 Wright et al. [41] 5 −86.2 (78.1%)
21 2005 Yao et al. [45] 16 31.7% (94.7%)
22 2005 Ockenga et al. [44] 9 −107.2 (74.4%) 3.1 (86.3%)
23 2005 Ockenga et al. [44] 9 −105.3 (75.4%) 3.0 (86.3%)
24 2005 Ockenga et al. [44] 10 −108.3 (74.8%) 3.2 (86.3%)
25 2005 Ockenga et al. [44] 10 −104.0 (77.3%) 3.0 (86.3%)
26 2012 Jacobson [46] 14 2.9 (86.0%) 0.39 (0.0%) 39.7% (94.7%)
Pooled estimate −96.7 (75.3%) 3.0 (85.6%) 0.46 (0.0%) 32.6% (94.9%)
CDAI: Crohn´s Disease Activity Index; BW: Body Weight, COM: Postoperative complications.
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Figure 4 shows this influence through the Baujat plot. The numbers shown in the figure correspond
to the articles shown in the table in the ID column. Notice that the studies 18, 10, and 2 correspond to
Greenberg et al., Fasth (b) et al., and Elson et al.
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proposed by Duval and Tweedie to analyze this asymmetry should show a lack of articles, and 
therefore, a publication bias. The results of this non-parametric analysis for the fixed-effects model 
and the random-effects model are shown in Table 4. These results show a possible publication bias 
in the albumin if a fixed-effects model is assumed; however, the random-effects models do not show 
Figure 4. Baujat plot for (a) Crohn’s Disease Acti it Index (CDAI), (b) Albumin (c) Body Weight, and
(d) Postoperative complications. The correspondence between the study and the number is shown in
Table 2 (Id, Omitting).
A Funnel Plot represents the effects observed in the different studies (x-axis), and the standard
error (y-axis). In the absence of heterogeneity and publication bias, the dots shown in the funnel
plot should jointly adopt the aspect of a funnel, with the wider part corresponding to the smaller
and more precise studies. A lack of symmetry could be ue to this publication bias. T e funnel
plot is shown in Figure 5, and a lack of symmetry can be observed. Therefore, the non-parametric
analysis proposed by Duval and Tweedie to analyze this asymmetry should show a lack of articles,
and therefore, a publication bias. The results of this non-parametric analysis for the fixed-effects model
and the random-effects model are shown in Table 4. These results show a possible publication bias in
the albumin if a fixed-effects model is assumed; however, the random-effects models do not show this
bias. The Copas analysis shows a p ssible publication bias and suggests that the benefits of PN on
umin could decrease from 3.01 to 2.0.
With respect to the meta-regression, the results are shown in Table 5. There is a dependence of the
CDAI score and albumin levels with the observed moment; we have to wait some days for confirming
the effects of the PN (p < 0.01).
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Table 4. Number of studies that should be added and the estimated effect size.
Trim-and-Fill Method Copas Method
Fix Model Random Model Random Model
Ns Effect Size Estimated95%CI Ns
Effect Size
Estimated 95%CI Ns
Effect Size
Estimated 95%CI
CDAI 2 −128.5 [−184.7; −72.3] 0 Unchanged 0 Unchanged
ALB 6 0.58 [−1.57; 2.74] 0 Unchanged 5 2.0 [0.16; 3.84]
BW 2 0.76 [−0.45; 1.98] 2 0.76 [−0.45; 1.98] 0 Unchanged
COM 3 0.04 [0.00; 0.37] 0 Unchanged 0 Unchanged
Ns: Number of studies added, CDAI: Crohn’s Disease Activity Index, ALB: Albumin, BW: Body Weight, COM:
Postoperative complications.
Table 5. Meta-regression.
Result Co-Variable T st of Moder tors
Intercep Surgery * QM p-Value
CDAI −96.68 - - - - - - - - -
ALB 1.39 2.47 1.02 0.312
BW 1.00 −0.96 0.54 0.461
Intercep Treatment (days) QM p-Value
CDAI −357.50 13.43 2.30 0.129
ALB 2.60 0.03 0.06 0.799
BW −0.84 0.08 1.028 0.310
COM 0.63 −0.01 1.56 0.212
Intercep Observed Moment (days) QM p-Value
CDAI 47.07 −10.77 7.95 0.005
ALB 0.54 0.05 7.42 0.006
BW −0.16 0.01 1.04 0.307
* Basis Group, No Surgery. CDAI: Crohn’s Disease Activity Index, ALB: Albumin, BW: Body Weight,
COM: Post-operative complications.
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4. Discussion
Our systematic review included a total of 15 clinical trials, which compiled information from
557 individuals with IBD, and who had an intervention with PN. All the studies had a broad reach,
and within the diverse effects found, BW, albumin, COM, and CDAI were the most common, allowing
us to conduct a meta-analysis to arrive at more complete conclusions.
PN implies the intravenous administration of a mix of macronutrients, micronutrients,
and electrolytes [47], and its main objective for IBD is to achieve bowel rest, correct nutritional deficits,
and the elimination of antigenic stimuli in the mucosa [48]. PN is commonly used during the acute
inflammatory phase in patients who are experiencing malnutrition, such as undernourishment [49].
This undernourishment could be a factor that affects micronutrient deficiency [50,51]. The results
from the systematic review show that the administration of PN significantly improved the levels
of ESR [35,38], cholesterol [46], total phospholipids [46], and serum albumin [37–40,44,46], without
producing clinical symptoms of hypoglycemia, independent of the method of interruption [43]. This
improvement of the albumin is mirrored in the results of the meta-analysis. The meta-regression
performed showed that the improvement could be greater a few days after the intervention.
The most common type of under-nourishment in patients with IBD was protein-energetic
malnutrition, mainly shown with weight loss [52,53]. This malnutrition could worsen due to diverse
surgical interventions that are necessary for emerging situations or when the medical treatment
fails [54]. Therefore, the nutritional support should be carefully chosen during the treatment and
before the surgery, based on a plan that is customized according to the patient [55]. Some authors
declare that PN results in an increase in BMI, helping to correct the individual’s malnutrition [23,56].
We have not collected the BMI; however we have identified the BW, which are equivalent terms in
adults, and the meta-analysis did not show the existence of a change in BW in patients with IBD when
administering PN.
The CDAI, developed by Best et al. [57], measures the activity of the disease in patients with
CD, with high values indicating a high activity of this pathology. Therefore, a reduction of this index
indicates an improvement. The clinical trials conducted showed improvements in this index, but while
these were significant in Jones [38], Greenberg et al. [39], Wright et al. [41], the results in Okenga [44]
were not. The meta-analysis shows a significant reduction of the values found for the CDAI, and this
decrease is accentuated days after the application of PN. These results are in agreement with diverse
expert researchers, who declare that PN could provide, along with a possible administration of drugs
such as infliximab, an improvement in this pathology [54,58,59].
Despite the accessibility to immunosuppressive drugs, antibiotic treatments, and fecal microbial
transplantation, patients experience a high rate of relapse of malabsorption due to intestinal
insufficiency [60]. In the case of individuals affected with CD, more than half are subjected to
some surgery, such as bowel resection within 10 years after the diagnosis, and a third of them require a
resection within the following five years [60]. This is the reason why PN could be fundamental with
respect to the survival of the patient, as its management has drastically improved in the last 10 years,
and the rate of related complications has notably decreased [60].
Likewise, the role of PN in postoperative complications is controversial. A recent meta-analysis
has shown that the pre-surgery nutritional supplementation reduced posterior complications after the
surgery in patients with CD, and more specifically, the TPN showed a tendency of being higher than the
standard of care without nutritional support, but without statistical significance [61]. Hypoalbuminemia
is associated with more postoperative complications, and it is sometimes a contraindication for surgery
that requires anastomosis without a protective ileostomy [62]. In our qualitative synthesis with respect
to the TPN, the results by Jacobson [46] concluded that it could be recommended for reducing the risk of
suffering from postoperative complications until achieving clinical remission, and Yao et al. [45] declare
that the perioperative PN may improve humoral immunity, reverse malnutrition and facilitate the
rehabilitation of the patient. However, Fasth et al. [36] indicate that the administration of postoperative
NPT does not result in a reduction of the complication rate after the surgery, although this difference
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could be due to the small sample utilized in this study. Our meta-analysis showed that the postoperative
complications utilizing PN exist, although the proportion is low.
The term bowel rest has been frequently linked to the use of PN with active IBD or important
complications such as the control of sepsis or imminent surgical procedures, and it is also theoretically
attractive because of the expectation that it could improve bowel inflammation by alleviating mechanical
trauma, bowel secretions, and antigenic challenge of the foods [35,63]. On the contrary, the results
by Jones [38] and Dickinson et al. [33] show that there are no differences in patients with CD treated
with either EN or TPN, and in patients with IBD treated solely with hydration or TPN. According
to Abad-Lacruz et al. [40], and Wright et al. [41], Gonzalez-Huix et al. [42], and Greenberg et al. [39],
EN results in significantly less frequent abnormalities in the LFT than TPN in patients with IBD,
the PN with bowel rest does not show evidence of having a better impact on the remission than EN in
patients with active CD, likewise, the EN is safer, cheaper and nutritionally effective in severe attacks
as compared with TPN, and there were no differences in the remission and activity of patients with
active CD.
All of this coincides with diverse studies and clinical practice guides, which indicate that
bowel rest is not necessary when nutritional therapy is utilized for managing the patients [48,64,65].
Therefore, they should be allowed to eat “ad libitum” when medical therapy is prescribed and when
different nutritional regimes exist through which clinical remission and repair of the mucosa can be
achieved [15,48,64–66].
Also, it has recently been shown that there is a high load of underfeeding, orders of “nil per os”
or a diet with clear liquids, which is unjustified for patients who are hospitalized with CU, especially
for patients admitted without evidence of an objective flare of the disease that could be provoking
iatrogenic malnutrition, so that bowel rest and the nutritional treatment should be given special
attention [67].
Despite being the first systematic review that deals with the general effects of PN on adult patients
with IBD, this article is not exempt from limitations. It is possible that the CONSORT questionnaire
was not the best for evaluating the NRCCT, and UNRCT reviewed; however, this limitation has been
tried to be avoided by adjusting the items of this tool to the type of study, as no questionnaire was
found that evaluated the RCCT, the NRCCT and the UNRCT [26,68]. Also, most of the studies were
somewhat old, with the most current one being from 2012, which could have reduced the score of this
tool on the methodological quality due to the lack of standard criteria at the time the clinical trials were
conducted. The UC and CD data have been combined to develop the meta-analysis for the variables
BW, albumin, and postoperative complications due to the low number of studies that separated these
diseases to elaborate their results. However, these clinical entities have different clinical courses.
The results derived from this work could help in clinical practice, to help the health professionals
with the creation of a guide oriented towards evaluating the addition of TPN within the set of medical
therapies for an adult patient diagnosed with IBD. However, as future lines of research, the use of
TPN with the said patients should be addressed, having in mind their quality of life, the manner of
administration, and the composition of the nutritional therapy in all the surgical procedures possible.
5. Conclusions
PN has shown to have efficacy for the treatment of IBD and is compatible with other medicines.
The CDAI and albumin improve, although the effect of PN is greater after a while. However, the effect
on the albumin could be less than the observed value in the meta-analysis, due to possible publication
bias. The body weight does not change after intervention. Postoperative complications utilizing PN
has been observed, although the proportion is low. More studies specifically referred to UC and CD
are needed to develop more concrete clinical results.
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